✦ LIBER ✦

Correlation of health-related quality of life with virological response and early treatment discontinuation in patients treated with pegylated (40 kDa) interferon alfa-2a (PEGASYS) compared with standard inferferon alfa-2a

✍ Scribed by Bernstein, David E.; Cooksley, Graham; Fried, Michael W.; Heathcote, Jenny E.; Pockros, Paul J.; Zeuzem, Stefan; Marinos, George; Rustgi, Vinod; Revicki, Dennis; Barker, Christopher M.

Book ID: 124140849
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 188 KB
Volume: 120
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(08)81897-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy, quality of life, safety, and t

Efficacy, quality of life, safety, and tolerability in patients with chronic hepatitis C treated with PEG (40 kDa) IFN α-2a (PEGASYS®) or standard interferon Alfa-2b/ribavirin (REBETRON™) combination therapy

✍ Kenneth D. Rothstein; Robert P. Perrillo; Joanne Imperial; Imtiaz Alam; Melissa 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 366 KB

Rapid virological response tailors the d

Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan

✍ Gill, Uzma; Aziz, Hafsa; Gill, Muzaffar Lateef 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 460 KB

499 The impact of sustained virological

499 The impact of sustained virological response (SVR) on health-related quality of life (HRQL) in patients with chronic hepatitis C (CHC) and persistently normal ALT levels (PNALT) treated with peginterferon alfa-2A (PEGASYS®) and ribavirin (COPEGUS®)

✍ C. O'Brien; N. Wintfeld; K.K. Patel; S. Zeuzem; M.L. Shiffman; M. Diago; A. Tran 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 62 KB

484 On-treatment predictors of sustained

484 On-treatment predictors of sustained biochemical and virological response in patients with HBeAg-negative chronic hepatitis B (CHB) treated with peginterferon α-2a (40 kDa) (PEGASYS®)

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 135 KB

Treatment with peginterferon alfa-2a (40

Treatment with peginterferon alfa-2a (40KD) (PEGASYS®) results in improved rates of response compared to conventional interferon in patients with HBEAG positive chronic hepatitis B harboring HBV genotypes B or ‘difficult-to-treat’ genotype C

✍ W.G.E. Cooksley; M.-Y. Lai; T. Piratvisuth; Y.-J. Wang; V. Mahachai; Y.-C. Chao; 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 135 KB

503 Early prediction of sustained virolo

503 Early prediction of sustained virological response (SVR) during treatment with peginterferon alfa-2A (40KD) (PEGASYS®) plus ribavirin (RBV) (COPEGUS®) in patients with chronic hepatitis C (CHC) and persistently normal alanine aminotransferase (ALT) levels

✍ P.J. Pockros; M. Diago; E. Gane; K.R. Reddy; D. Prati; M.L. Shiffman; P. Farci; 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 65 KB